水痘减毒活疫苗的现状与展望

Current status and prospects of live varicella vaccine.

作者信息

Takahashi M

机构信息

Research Institute for Microbial Diseases, Osaka University, Japan.

出版信息

Vaccine. 1992;10(14):1007-14. doi: 10.1016/0264-410x(92)90109-w.

DOI:10.1016/0264-410x(92)90109-w

PMID:1335196

Abstract

Since its development in 1974 the Oka strain live attenuated varicella vaccine has been tested in healthy and immunocompromised adults and children. Its safety and efficacy have been established and it is now licensed for general use in Japan and Korea, and for immunocompromised patients in several other countries. Possibilities for the future include its use to prevent zoster in the elderly, its incorporation in a multivalent vaccine and its use as a vehicle to express foreign genes in recombinant vaccines.

摘要

自1974年研发以来，Oka株水痘减毒活疫苗已在健康及免疫功能低下的成人和儿童中进行了测试。其安全性和有效性已得到证实，目前已在日本和韩国获得一般用途许可，并在其他几个国家用于免疫功能低下的患者。未来的可能性包括用于预防老年人的带状疱疹、纳入多价疫苗以及用作在重组疫苗中表达外源基因的载体。